MetaCap

Cabaletta Bio Inc. (CABA)

NASDAQ: CABAHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

0.9361-0.0739 (-7.32%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

CABA stock chart

Technical analysis

Key statistics

All statistics
Market cap
$201.94M
EPS (TTM)
-$1.33
52-week range
0.93 – 4.23
Day range
0.93 – 1.03
Volume / Avg
3.73M / 5.15M
Beta
—

52-week range

$0.93$4.23

CABA stock today

Cabaletta Bio (CABA) closed at $0.9361 on Nov 20, down 7.32% (-$0.0739), versus the S&P 500's 3.70% decline. Shares are 77.9% below their 52-week high of $4.23, set on May 6, 2026 and 0.7% above the 52-week low of $0.93, near the bottom of the past year's range. CABA is down 57.3% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 55.0%.

Cabaletta Bio has posted a net loss over the last twelve months (EPS of -$1.33), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Cabaletta Bio

Company profile

Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with autoimmune diseases. The company's lead product candidate is resecabtagene autoleucel, a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T, which is in Phase 1/2 clinical trials for the treatment of dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, juvenile myositis, lupus nephritis, systemic lupus erythematosus, relapsing and progressive multiple sclerosis, mucocutaneous and mucosal pemphigus vulgaris (PV), systemic sclerosis, and generalized myasthenia gravis. It also develops DSG3-CAART, a CAAR T cell therapy that is in Phase 1 clinical trial for the treatment of mucosal PV; and MuSK-CAART, an investigational cell therapy in Phase 1 trial for treating patients with anti-muscle-specific kinase (MuSK) antibody positive myasthenia gravis.

Industry
Biotechnology: Biological Products (No Diagnostic Substances)
CEO
Dr. Steven A. Nichtberger M.D.
Headquarters
Philadelphia, PA
Employees
154
IPO year
2019

Financial highlights

Full financials

Cabaletta Bio reported a net loss of $167.9 million, compared with a loss of $115.9 million a year earlier. Diluted earnings per share came in at -$2.10.

Cabaletta Bio annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue—————
Growth—————
Net income$-167.86M$-115.86M$-67.67M$-52.98M$-46.29M
EPS (diluted)$-2.10$-2.34$-1.65$-1.81$-1.80

Analyst forecast

Forecast

Consensus (10 analysts)

strong_buy

Avg. price target

$11.75+1155.21%

  • Strong buy 1
  • Buy 7
  • Hold 2
  • Sell 0
  • Strong sell 0

Target range

Low $3.00High $20.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 9, 2026
EPS actual vs est.
$-0.28 vs $-0.33
Surprise
+15.15%

CABA news

All CABA news

Cabaletta Bio peers

Health Care sector
CABA peer companies
CompanyPrice% ChgMarket capCompare
LCTXLineage Cell Therapeutics Inc.0.7719-5.87%$195.26Mvs CABA
IPSCCentury Therapeutics Inc.1.17-11.74%$211.56Mvs CABA
ARTVArtiva Biotherapeutics Inc.3.78-1.31%$186.85Mvs CABA
ALLOAllogene Therapeutics Inc.0.6277-5.88%$217.48Mvs CABA
IKTInhibikase Therapeutics Inc.1.32+1.54%$185.16Mvs CABA
SCTXScribe Therapeutics Inc.12.07-8.70%$228.58Mvs CABA
CGENCompugen Ltd.1.84-2.13%$174.29Mvs CABA
AUTLAutolus Therapeutics plc ADR0.9073-7.38%$241.65Mvs CABA

Indexes, lists and sector

Cabaletta Bio stock FAQ

What is Cabaletta Bio's stock price today?

CABA last traded at $0.9361 as of Nov 20, 4:00 PM EST, down 7.32% on the day. Prices are delayed at least 15 minutes.

Who is Cabaletta Bio's CEO?

Dr. Steven A. Nichtberger M.D. is the chief executive officer of Cabaletta Bio Inc., which has about 154 employees.

What is the CABA 52-week high?

The 52-week high for CABA is $4.23 and the 52-week low is $0.93. The stock is currently 77.9% below its high.

Compare CABA